GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Net Cash per Share

Firebrick Pharma (ASX:FRE) Net Cash per Share : A$0.01 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Firebrick Pharma's Net Cash per Share for the quarter that ended in Dec. 2023 was A$0.01.

The historical rank and industry rank for Firebrick Pharma's Net Cash per Share or its related term are showing as below:

ASX:FRE' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5   Med: 7.15   Max: 15.5
Current: 5.7

During the past 3 years, the highest Price-to-Net-Cash Ratio of Firebrick Pharma was 15.50. The lowest was 5.00. And the median was 7.15.

ASX:FRE's Price-to-Net-Cash is ranked better than
59.14% of 257 companies
in the Drug Manufacturers industry
Industry Median: 6.82 vs ASX:FRE: 5.70

Firebrick Pharma Net Cash per Share Historical Data

The historical data trend for Firebrick Pharma's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Net Cash per Share Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23
Net Cash per Share
0.06 0.04 0.01

Firebrick Pharma Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Net Cash per Share 0.04 0.03 0.01 0.01

Competitive Comparison of Firebrick Pharma's Net Cash per Share

For the Drug Manufacturers - General subindustry, Firebrick Pharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Firebrick Pharma's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's Price-to-Net-Cash falls into.



Firebrick Pharma Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Firebrick Pharma's Net Cash per Share for the fiscal year that ended in Jun. 2023 is calculated as

Net Cash per Share (A: Jun. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(2.355-0.506-0)/176.247
=0.01

Firebrick Pharma's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1.305-0.356-0)/178.047
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Firebrick Pharma  (ASX:FRE) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Firebrick Pharma Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Firebrick Pharma (ASX:FRE) Business Description

Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of Nasodine, a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold.

Firebrick Pharma (ASX:FRE) Headlines

No Headlines